Compare Heron Therapeutics Inc (HRTX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Plby Group Inc — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Plby Group Inc trades at $1.26 (market cap $162.94M). The key difference: Plby Group Inc is far larger — about 2.7× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| HRTX | PLBY | |
|---|---|---|
Market Cap | $61.47M | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $2.71 |
52-Week Low | $0.32 | $1.11 |
Enterprise Value | $168.21M | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
PLBY trades at $1.18, down 3.28% recently, with a bearish technical signal. The company reported Q2 2026 revenue growth and positive operating cash flow, with net income turning positive in 2026 after years of losses. Valuation ratios like P/E of 68 and P/S of 1.2 appear elevated relative to profitability. Recent news highlights inclusion in Russell indexes and leadership expansion.
The outlook is cautiously optimistic with improving fundamentals, but high debt and thin margins pose risks. Analyst consensus is strongly bullish with 75% buy ratings, yet the stock faces execution risks in licensing growth and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
